PROCEPT BioRobotics Corporation reported strong financial results for the second quarter ended June 30, 2025, with total revenue increasing 48% year-over-year to $79.2 million. U.S. revenue grew 46% to $69.6 million, driven by system sales to new hospital customers and a 58% increase in U.S. handpiece and consumable revenue to $43.1 million.
The company's gross margin expanded to 65% in Q2 2025, up from 59% in the prior year period, attributed to improved operational efficiencies, overhead absorption, and higher average selling prices on U.S. robotic systems. The net loss narrowed to $19.6 million from $25.6 million, and Adjusted EBITDA loss improved to $8.0 million from $17.9 million.
PROCEPT BioRobotics raised its full-year 2025 total revenue guidance to $325.5 million, representing 45% growth, and increased international revenue guidance to $36.0 million, implying 50% growth. The company also noted that tariff-related cost headwinds for 2025 were lowered to $1 million-$2 million from an earlier estimate of $5 million, further supporting margin projections.
The U.S. installed base of robotic systems reached 595 as of June 30, 2025, with 48 new HYDROS systems sold in Q2 2025 at an average selling price of approximately $455,000 for greenfield placements. The 2026 Medicare proposed Outpatient Prospective Payment System (OPPS) sets facility reimbursement at $9,705 for hospital-based coagulation therapy, a 5.6% increase from 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.